A review of atrial fibrillation (AF) and AF-related stroke public health policies

A robust ten-country review of the available screening, awareness, and prevention policies for atrial fibrillation and atrial fibrillation-related stroke.

Atrial fibrillation (AFib) is often asymptomatic--until it leads to complications or a stroke. In the US and EU, the annual economic burden of AFib and AFib-related stroke reaches into the billions ($/€), but governmental policies and clinical guidelines vary. To understand what works, the BMS–Pfizer Alliance conducted a comprehensive policy analysis across 10 countries with known clinical and public health AFib interventions, and identified actions for developing an effective health response, as well as emerging tools to support these efforts. DOWNLOAD HERE